OncoSil MEDICAL

CEO AGM Presentation

25 October 2022

Targeted Approach • Positive Impact

Introduction

The prognosis for pancreatic cancer patients has remained almost unchanged for over 40 years[1] with a reported five-year survival rate for the disease of 10%[2]



References: 1. Cancer Research UK. www.cancerresearchuk.org/health-professional/cancer-statistics/survival/common-cancers-compared#heading-Three (accessed November 2021)
2. American Cancer Society. Cancer Facts & Figures 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

OncoSil Medical's targeted approach delivers a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients

Board and Management Team with Experience and Expertise

Nigel Lange
Managing Director & CEO

30+ years experience in medical device industry

Served as Group COO and Interim Group CEO of Sirtex Medical

Otto Buttula
Non-executive Chairman

Extensive experience in investment research, funds management and IT and previously a director of Imugene (ASX:IMU) and currently Chairman of Rhythm Biosciences (ASX:RHY) & HITIQ (ASX: HIQ)

Prof Ricky Sharma
Non-executive Director

International authority on translation of radiobiology from the lab to the clinic and on the multi-modality treatment of cancer with precision radiotherapy. Currently VP Clinical Affairs at Varian (Siemens)

Brian Leedman
Non-executive Director

Experienced company director, Investor Relations specialist and biotechnology entrepreneur. Co-founded five healthcare companies on the ASX including ResApp Health (ASX:RAP) acquired by Pfizer in 2022

Dr Jon Bell MD
Chief Medical Officer

8+ years experience as an Interventional Radiologist and an internationally recognised expert in Interventional Oncology

David Turner
Head of Medical Affairs

40+ years experience in pharmaceutical, medical device and health technology industries

Henk Tissing
Director of Clinical Development

25+ years industry experience in oncology with pharmaceuticals and medical devices.

Senior Clinical development roles at Sirtex Medical, BTG, A-Z & Sanofi Aventis

Karl Pechmann
Chief Financial Officer

20+ years of finance experience having held several senior roles for listed and multi-national organisations

David James
Head, Manufacturing & Operations

25+ years of pharmaceutical and manufacturing operations experience

OncoSil™ Device

Overview

- OncoSil™ is intended for the treatment of **locally advanced unresectable pancreatic cancer**, in combination with gemcitabine-based chemotherapy.
- OncoSil™ is a **single-use** brachytherapy device comprised of microparticles and a diluent.
- OncoSil™ is **implanted directly** into a pancreatic tumour via injection under **endoscopic ultrasound** guidance.
- **98%** of all radiation is delivered within **81** days of injection causing direct damage to cancer cell DNA, and ultimately shrinking tumour masses when the cells die.

Oncosil Device Animation



What we have accomplished

Experienced team in place

CE Marking obtained

Innovation Funding (NUB) approved
German funding of the OncoSil™ device

Enabled HDE pathway for bile duct cancer in the US
Application submitted to FDA

PanCO Study completed
and submitted to peer-reviewed journal
Data presented at leading oncology congresses

Breakthrough device designation achieved
in US, EU, UK and Singapore

Current market approvals

Europe (CE Mark)
United Kingdom
Switzerland
Singapore
Malaysia
Hong Kong
New Zealand
Turkey
Israel

FDA: Food and Drug Administration
HDE: Humanitarian Device Exemption
*Distal cholangiocarcinoma (DCC or bile duct cancer)

Surgical Resection remains the gold standard

The only potentially curative treatment for pancreatic cancer[1]



30% of LAPC patients shows metastatic progression with 3-6 months[9,10]

References: 1. Ducreux M et al. Ann Oncol 2015; 26 (Suppl 5): v56–68. 2. Gemenetzis G et al. Ann Surg 2019; 270: 340–347. 3. Chang JS et al. Cancer Res Treat 2018; 50: 562–574 (suppl data). 4. Burris HA 3rd et al. J Clin Oncol 1997; 15: 2403–2413. 5.Von Hoff DD et al. N Engl J Med 2013; 369: 1691–1703. 6. Conroy T et al. N Engl J Med 2011; 364: 1817–1825. 7. Balaban EP et al. J Clin Oncol 2016; 34: 2654–2668. 8. National Comprehensive Cancer Network (NCCN) Clinical Practive Guidelines in Oncology: Pancreatic adenocarcinoma. Version 1.2020. 9. Huguet et al. J Clin Oncol 2010. 10. Mukherjee et al, Lancet Oncol 2013.

Abbreviations
CT: Chemotherapy
ICT: Induction chemotherapy
CCRT: Concurrent chemoradiation therapy

PanCO results showing compelling evidence of downstaging

OncoSil™ converted patients with unresectable locally advanced pancreatic cancer (LAPC) to resection, transforming their prognosis and substantially extending survival

What did the PanCO study show?



Adding OncoSil™ to chemotherapy led to a high proportion of patients having substantial reductions in their tumour volume (range +11% to –90%), with 57% having a >50% reduction[2]

1 in 3 patients with unresectable LAPC receiving OncoSil™ plus chemotherapy became eligible for curative surgery[2]

Nearly 1 in 4 patients (23.8%) with unresectable LAPC receiving OncoSil™ plus chemotherapy underwent surgery with curative intent[2]

At the end of the PanCO Study with a follow-up of 32 months, 6 of the 10 resected patients remained alive, 5 without any evidence of disease (26.4–35.3 months from enrolment in the study)[2,3]

References: **1.** Allerdice S et al. Naïve indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy, versus standard-of-care treatment in unresectable locally advanced pancreatic cancer. Presented at the World Congress of GI Cancer, Annals of Oncology 2020: 31 (Suppl 3); Abstract P-260. **2.** Ross PJ et al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/ nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open February 2022; 7 (1): 100356. **3.** Data on file. OncoSil Medical Ltd.

Sales and training activities to date

During the year, the OncoSil™ team has progressed on key site start-up activities

- Key experienced sales, marketing and training team in place – no need for any expansion of the team in the near term
- Distributors have been identified in other markets to expand the OncoSil footprint globally
- Training and certification of sites complete in 24 sites in EMEA and the UK
- 21 sites have received ethics approval for the OSPREY post marketing registry
- Patient treatments commenced in Spain and awarded first commercial agreement for patient doses

OncoSil™ launched in:

This is where we are today

Market access and clinical development supporting sales activities

Sales team fully engaged with targeted Key Opinion Leaders to improve knowledge base of OncoSil™ technology.

- Personal Key Opinion Leader (KOL) interaction now possible following lilting of restrictions

Detailed health economic and market access analysis.

- Seeking reimbursement in several European jurisdictions
- Achievement of UK reimbursement with two leading private health insurers
- Working with private health insurers to agree reimbursement of the OncoSil™ device for their clients
- Have had treatments already funded by private health insurers

Identifying programs for fully funded, government sponsored clinical trials including paid patient doses in the EU.

- NUB Status 1 Innovation Funding approved at 25 hospitals in Germany
- GBA fully funded clinical trial in Germany approved

Clinical Development pathway

- Preparation for commencement of TRIPP FFX clinical trial – 15 sites enrolled
- Investigating possible expansion of OncoSil device in future indications or in combination with other treatment regimens

Ongoing dialogue with the FDA on the following:

- Concerning approval of the HDE in dCCA to facilitate rapid entry into the US market



FY 2023 Impending Deliverables

1. Accelerate commercial sales of the OncoSil™ device.
2. Pursue additional reimbursement programs.
3. Geographic expansion of sales.
4. Expand authorised user base.
5. Expand clinical data.
6. Progress FDA discussion for HDE in dCCA (distal cholangiocarcinoma).
7. Diversify manufacturing to reduce production costs and gain economies of scale.
8. Investigate device use in other solid tumour indications, potentially via strategic partnership.
9. Strategic initiatives and partnerships.

Disclaimer

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 25 October 2022.

Nigel Lange

CEO & Managing Director

E: nigel.lange@oncosil.com

OncoSil Medical Ltd
www.oncosil.com

T: +49 160 9642 4981

Targeted Approach • Positive Impact